Significant progress has been made in the treatment of acute myeloid leukemia (AML). Steady gains in clinical research and a renaissance of genomics in leukemia have led to improved outcomes. The recognition of tremendous heterogeneity in AML has allowed individualized treatments of specific disease entities within the context of patient age, cytogenetics, and mutational analysis. The following is a comprehensive review of the current state of AML therapy and a roadmap of our approach to these distinct disease entities.
|Original language||English (US)|
|Number of pages||13|
|Journal||Clinical Lymphoma, Myeloma and Leukemia|
|State||Published - Mar 1 2015|
- Targeted therapy
ASJC Scopus subject areas
- Cancer Research